List of seven medical conditions that could exempt you from paying any council tax
According to MoneySavingExpert (MSE), hundreds of thousands of people in England, Scotland and Wales could be entitled to this reduction and not claiming it.
It comes after council tax bills were put up in April, with almost all councils hiking bills by up to, or close to, the maximum rate permitted. On average, council tax bills have increased by 5.1% in the previous two years.
READ MORE: DWP confirms group that aren't eligible for Winter Fuel Payment under new rules
READ MORE: Record-breaking footballer and TV sports star opens HMO in Oldham
Since April 1, the average annual band D bill - the standard measure of council tax - is £2,280 a year in total. That's an increase of £109 from last year and a 20% rise from five years ago when the average bill was £1,898.
Join the Manchester Evening News WhatsApp group HERE
But people who are classed as "severely mentally impaired" may be able to claim up to 50% off their bill - or in the most severe cases have the whole bill wiped entirely.
According to the government, there are two criteria a person needs to meet to qualify for the discount:
they must have a certificate from a medical professional, such as a GP, to say they are "severely mentally impaired"
they must be able to prove they are claiming certain benefits
The government does not define what it means by "severely mentally impaired" but MSE suggests there are several conditions that may qualify for the discount.
According to MSE, the following conditions may qualify:
Dementia (including Alzheimer's)
Parkinson's
Severe learning difficulties
Multiple sclerosis
Cerebral palsy
Severe stroke
Schizophrenia
However, whether the discount is granted or not will depend on an individual's own circumstances and a diagnosis of one of the above does not necessarily mean the discount will be granted.
MSE explains: "You can be diagnosed as SMI as a result of a range of conditions – which could include things like dementia, Schizophrenia, multiple sclerosis, having had a stroke, or having had an accident which permanently affects your intelligence and social functioning.
"Many conditions can underlie being SMI, but no condition means a person is definitely also SMI. Being SMI is a doctor's diagnosis in its own right."
To qualify for the discount, a doctor must provide a certificate confirming that the patient is "severely mentally impaired".
According to the law, a person may be classed as such if they have "a severe impairment of intelligence and social functioning (however caused) which appears to be permanent".
To qualify for the discount you must also be able to prove you are claiming certain benefits, or in some cases, just that you are eligible for them.
Qualifying benefits may include:
Attendance Allowance
Universal Credit
Disability Living Allowance
Income Support
Personal Independence Payment
Further information can be found on the gov.uk website and local authorities can provide full eligibility criteria for the discount on their websites.
If you live on your own then your council tax discount will be 100% - meaning you won't have to pay any council tax.
You may get 50% off your council tax bill if you only live with people who are 'disregarded' from council tax - people who are not counted when working out how many people are in a household, including people under 18, people on certain apprenticeship schemes, full-time students, live-in carers and diplomats.
If you live with one other person who is not discounted then you can get a 25% discount.
You may also be able to get back payments, depending on which local council you pay your tax to.
According to MSE, some councils will backdate the discount by six years but each council has its own policy and they are not legally obliged to backdate the discount.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Cognito achieves enrolment target in trial of Spectris system for Alzheimer's
Cognito Therapeutics has reached its enrolment goal for the randomised, sham-controlled HOPE Study investigating the Spectris AD system's efficacy and safety in treating Alzheimer's disease. The double-blind trial, with 670 subjects enrolled, is set to use the company's neuromodulating device at home for 12 months. Carried out across 70 US clinical sites, the trial will be followed by a 12-month open-label extension trial. According to the company, the Spectris AD system will deliver synchronised light and sound stimulation at the 40Hz gamma frequency, which has previously shown promise in the OVERTURE feasibility study by preserving corpus callosum structure in subjects with Alzheimer's. Results from the study indicated a 76% and 77% decrease in cognitive and functional decline, respectively, and significant white matter preservation with a 69% decrease in whole brain atrophy over six months. Subjects in the HOPE Study's treatment group will receive Active Sensory Stimulation System treatment once a day while the control group will use a Sham Sensory Stimulation System. Study visits for consent, screening, and baseline assessments are scheduled, followed by three, six, nine (by phone), 12, and 13 months safety follow-ups. The primary aim of the study is to evaluate Spectris' efficacy in slowing Alzheimer's progression against sham for mild to moderate patients, measured functionally by the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) assessment and the Mini-Mental State Exam (MMSE). A subset of clinical sites will participate in a substudy to assess additional fluid biomarkers. Subjects at these sites will undergo lumbar punctures to collect cerebrospinal fluid at baseline, three months, and 12 months. Cognito Therapeutics CEO Christian Howell said: 'Completing enrolment in this landmark trial marks a major step forward in our mission to deliver a better treatment option for people living with neurodegenerative conditions such as Alzheimer's.' The system remains investigational and is not yet available for sale. In 2023, Cognito secured $73m in Series B funding to further develop its wearable neuromodulation device for Alzheimer's. "Cognito achieves enrolment target in trial of Spectris system for Alzheimer's" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Miami Herald
3 days ago
- Miami Herald
Mayo Clinic's AI tool identifies 9 dementia types, including Alzheimer's, with one scan
ROCHESTER, Minn. - Mayo Clinic researchers have developed a new artificial intelligence (AI) tool that helps clinicians identify brain activity patterns linked to nine types of dementia, including Alzheimer's disease, using a single, widely available scan - a transformative advance in early, accurate diagnosis. The tool, StateViewer, helped researchers identify the dementia type in 88% of cases, according to research published online on June 27, 2025, in Neurology, the medical journal of the American Academy of Neurology. It also enabled clinicians to interpret brain scans nearly twice as fast and with up to three times greater accuracy than standard workflows. Researchers trained and tested the AI on more than 3,600 scans, including images from patients with dementia and people without cognitive impairment. This innovation addresses a core challenge in dementia care: identifying the disease early and precisely, even when multiple conditions are present. As new treatments emerge, timely diagnosis helps match patients with the most appropriate care when it can have the greatest impact. The tool could bring advanced diagnostic support to clinics that lack neurology expertise. The rising toll of dementia Dementia affects more than 55 million people worldwide, with nearly 10 million new cases each year. Alzheimer's disease, the most common form, is now the fifth-leading cause of death globally. Diagnosing dementia typically requires cognitive tests, blood draws, imaging, clinical interviews and specialist referrals. Even with extensive testing, distinguishing conditions such as Alzheimer's, Lewy body dementia and frontotemporal dementia remains challenging, including for highly experienced specialists. StateViewer was developed under the direction of David Jones, M.D., a Mayo Clinic neurologist and director of the Mayo Clinic Neurology Artificial Intelligence Program. 'Every patient who walks into my clinic carries a unique story shaped by the brain's complexity,' Dr. Jones says. 'That complexity drew me to neurology and continues to drive my commitment to clearer answers. StateViewer reflects that commitment - a step toward earlier understanding, more precise treatment and, one day, changing the course of these diseases.' To bring that vision to life, Dr. Jones worked alongside Leland Barnard, Ph.D., a data scientist who leads the AI engineering behind StateViewer. 'As we were designing StateViewer, we never lost sight of the fact that behind every data point and brain scan was a person facing a difficult diagnosis and urgent questions,' Dr. Barnard says. 'Seeing how this tool could assist physicians with real-time, precise insights and guidance highlights the potential of machine learning for clinical medicine.' Turning brain patterns into clinical insight The tool analyzes a fluorodeoxyglucose positron emission tomography (FDG-PET) scan, which shows how the brain uses glucose for energy. It then compares the scan to a large database of scans from people with confirmed dementia diagnoses and identifies patterns that match specific types, or combinations, of dementia. Alzheimer's typically affects memory and processing regions, Lewy body dementia involves areas tied to attention and movement, and frontotemporal dementia alters regions responsible for language and behavior. StateViewer displays these patterns through color-coded brain maps that highlight key areas of brain activity, giving all clinicians, even those without neurology training, a visual explanation of what the AI sees and how it supports the diagnosis. Mayo Clinic researchers plan to expand the tool's use and will continue evaluating its performance in a variety of clinical settings. Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Yahoo
3 days ago
- Yahoo
Is Quest Diagnostics Stock a Smart Pick for Your Portfolio Now?
Quest Diagnostics Inc. DGX is investing in advanced diagnostics to deliver and scale innovative services that improve patient care and drive growth. The company's growth strategy includes pursuing value-creating, strategically aligned acquisitions using a disciplined investment approach. A strong focus on cost management adds to the the company continues to navigate a shifting U.S. healthcare system marked by several inherent risks. A rising debt burden is also concerning. In the past year, this Zacks Rank #2 (Buy) stock has rallied 27.3% compared with the industry's 6.6% growth and the S&P 500 composite's 11.7% rise. The renowned provider of diagnostic information services has a market capitalization of $20.05 billion. Quest Diagnostics has an earnings yield of 5.4% compared with the industry's yield of 4.3%. The company's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 2%. Strong Potential of Advanced Diagnostics: In Advanced Diagnostics, DGX is focused on five major clinical areas — advanced cardiometabolic, autoimmune, brain health, oncology, and women's and reproductive health — to enable growth across its customer channels. In the first quarter of 2025, each of these areas delivered solid double-digit growth, significantly contributing to the total revenues. Brain Health gained from robust demand for AD-detect blood tests for assessing Alzheimer's disease risk, with plans underway to expand the portfolio with new biomarkers for Alzheimer's and other forms of dementia. Image Source: Zacks Investment Research In women's and reproductive health, Quest Diagnostics introduced a new self-collection option for a specimen for HPV cervical cancer screening at a doctor's office. The company also started receiving commercial orders for the Haystack MRD test for assessing the early risk of cancer recurrence. It anticipates generating revenues from the test this year. Progress With Acquisition Strategy: Quest Diagnostics puts a high emphasis on accretive outreach purchases, as well as other independent labs, to support its growth objectives. In 2024, the company completed eight acquisitions, all of which align with its criteria for growth, profitability and returns. The addition of LifeLabs strengthened its foothold in the Canadian market and created new growth opportunities. The company acquired Allina Health, a leading nonprofit health system serving Minnesota and western Wisconsin, and the laboratory business of three physician groups in New York. To increase the adoption of AI and digital pathology, Quest Diagnostics acquired PathAI Diagnostics. In addition, it completed the acquisition of lab assets from Ohio Health and University Hospitals, two leading nonprofit health systems in Ohio. For 2025, Quest Diagnostics plans to slow its acquisition pace and prioritize maximizing productivity from last year's completed deals. Strategic Imperative to Drive Operational Excellence: The company continues to target 3% annual cost savings and productivity improvements through its Invigorate cost-savings program, which includes structured plans to drive savings and improve productivity across the value chain. Quest Diagnostics is also automating several areas of its laboratories, from tuberculosis testing to cervical cancer screening. The company also recently announced Project Nova, a new IT initiative to modernize its systems architecture, reduce IT costs over the long term and support its ability to optimize data insights and GenAI. In March 2025, DGX announced a collaboration with Google Cloud to streamline data management and employ GenAI to personalize customer and employee experiences. Escalating Debt Level: As of the end of the first quarter of 2025, the long-term debt totaled $5.86 billion, while cash and cash equivalents were just $188 million. The current portion of the debt was $1 million. Moreover, a higher debt level induces higher interest payments, which come along with the risk of failure to pay the same. The times interest ratio, which indicates the company's capacity to pay interest, slipped 0.6% sequentially to 6.3%. Unstable Macroeconomic Backdrop: Government payers, such as Medicare and Medicaid, have taken steps to reduce the utilization and reimbursement of healthcare services, including clinical testing services. Further, the industry-wide trend of consolidation has led to larger insurance plans with significant bargaining power, making it difficult for Quest Diagnostics to negotiate fee arrangements and possibly limiting access to its newer innovative solutions. Also, with the new U.S. administration in place, any regulatory changes could have a material adverse effect on the company's business. The Zacks Consensus Estimate for Quest Diagnostics' 2025 earnings per share (EPS) has increased 1 cent to $9.70 in the past 30 days. The consensus estimate for the company's 2025 revenues is pegged at $10.78 billion. This suggests 9.2% growth from the year-ago reported number. Some other top-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Cardinal Health CAH and Cencora COR. Phibro Animal Health has an estimated long-term earnings growth rate of 26% compared with the industry's 15.7%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 30.6%. Its shares have rallied 49.8% compared with the industry's 14.3% growth in the past year. PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. Cardinal Health, currently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 10.9% compared with the industry's 9.9% growth. Shares of the company have surged 74.1% compared with the industry's modest 0.9% gain. CAH's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.3%. Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.3% compared with the industry's 3.7%. Shares of the company have rallied 34.1% against the industry's 14.5% decline. COR's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data